TERT promoter mutations and melanoma survival: A comprehensive literature review and meta-analysis.
Melanoma
Meta-analysis
Review
Survival
Telomerase reverse transcriptase gene promoter
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
23
01
2020
revised:
02
01
2021
accepted:
27
02
2021
pubmed:
7
3
2021
medline:
21
4
2021
entrez:
6
3
2021
Statut:
ppublish
Résumé
We conducted a systematic review and meta-analysis of the association between somatic mutations of the TERT gene promoter and melanoma survival. Data from nineteen independent studies (>2,500 melanoma overall) were pooled using random effects meta-analysis models. TERT-mutated melanoma patients had a significantly worse overall survival (OS) (summary hazard ratio 1.43, 95 % confidence intervals (CI) 1.05-1.95) compared to wild-type ones. The association became stronger when combining risk estimates for overall and melanoma-specific survival (MSS) (1.52, 95 % CI 1.14-2.02), and when restricting the analysis to studies mostly based on invasive non-acral cutaneous melanomas (1.77, 95 % CI 1.00-3.15). Limited, yet suggestive evidence of a detrimental effect of TERT promoter mutations on melanoma prognosis emerged also for other survival measures (e.g. disease-free and distant metastasis-free survival). We found suggestive evidence of a detrimental effect of TERT mutations on melanoma patients' survival.
Identifiants
pubmed: 33675908
pii: S1040-8428(21)00076-7
doi: 10.1016/j.critrevonc.2021.103288
pii:
doi:
Substances chimiques
TERT protein, human
EC 2.7.7.49
Telomerase
EC 2.7.7.49
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103288Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.